ATE355826T1 - Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten - Google Patents

Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Info

Publication number
ATE355826T1
ATE355826T1 AT98957320T AT98957320T ATE355826T1 AT E355826 T1 ATE355826 T1 AT E355826T1 AT 98957320 T AT98957320 T AT 98957320T AT 98957320 T AT98957320 T AT 98957320T AT E355826 T1 ATE355826 T1 AT E355826T1
Authority
AT
Austria
Prior art keywords
nucleic acids
lipid
double layers
cells
lipid double
Prior art date
Application number
AT98957320T
Other languages
English (en)
Inventor
Edward G Saravolac
Yuan-Peng Zhang
Jeffery J Wheeler
Pieter R Cullis
Peter Scherrer
Ljiljana D Kojic
Olga Ludkovski
Original Assignee
Inex Pharmaceuticals Corp
Edward G Saravolac
Yuan-Peng Zhang
Jeffery J Wheeler
Pieter R Cullis
Peter Scherrer
Ljiljana D Kojic
Olga Ludkovski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp, Edward G Saravolac, Yuan-Peng Zhang, Jeffery J Wheeler, Pieter R Cullis, Peter Scherrer, Ljiljana D Kojic, Olga Ludkovski filed Critical Inex Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE355826T1 publication Critical patent/ATE355826T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98957320T 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten ATE355826T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6347397P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE355826T1 true ATE355826T1 (de) 2007-03-15

Family

ID=22049444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98957320T ATE355826T1 (de) 1997-10-10 1998-10-09 Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten

Country Status (6)

Country Link
EP (1) EP1023048B1 (de)
AT (1) ATE355826T1 (de)
AU (1) AU1360499A (de)
CA (2) CA2309727C (de)
DE (1) DE69837274T2 (de)
WO (1) WO1999018933A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
IL147089A0 (en) * 1999-07-15 2002-08-14 Inex Pharmaceuticals Corp Methods of preparing lipid-encapsulated therapeutic agents
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6242188B1 (en) 1999-07-30 2001-06-05 Applied Gene Technologies, Inc. Sample processing to release nucleic acids for direct detection
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
AU2000267686A1 (en) * 2000-08-10 2002-02-25 Applied Gene Technologies, Inc. Compositions and methods for nucleic acids sample processing and amplification
WO2002028367A1 (fr) 2000-10-04 2002-04-11 Kyowa Hakko Kogyo Co., Ltd. Procede de revetement de particules fines avec un film de lipides
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
EP1648519B1 (de) 2003-07-16 2014-10-08 Protiva Biotherapeutics Inc. Lipid verkapselte interferierende rns
AU2004272646B2 (en) 2003-09-15 2011-11-24 Arbutus Biopharma Corporation Polyethyleneglycol-modified lipid compounds and uses thereof
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
AU2005306533B2 (en) * 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
EP2125031B1 (de) * 2006-12-19 2017-11-01 Marina Biotech, Inc. Lipide und lipidanordnungen mit transfektionsverstärkungselementen
CA2713232C (en) 2008-01-25 2020-05-05 P53, Inc. P53 biomarkers
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
IL292615B2 (en) 2009-07-01 2023-11-01 Protiva Biotherapeutics Inc Nucleic acid-lipid particles, preparations containing them and their uses
WO2011056682A1 (en) 2009-10-27 2011-05-12 The University Of British Columbia Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
NZ600616A (en) 2009-12-01 2014-11-28 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
KR102128248B1 (ko) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
RU2620077C1 (ru) * 2015-11-26 2017-05-22 Ярославов А.А. Способ получения иммобилизованных бислойных везикул
EP4219715A3 (de) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3775211B1 (de) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna kompositionen und methoden zu deren verwendung
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
KR20230160872A (ko) 2021-03-26 2023-11-24 미나 테라퓨틱스 리미티드 Tmem173 sarna 조성물 및 사용 방법
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508231A (ja) * 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質／核酸複合体を含む送達ビヒクル
ATE285477T1 (de) * 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer

Also Published As

Publication number Publication date
CA2792406A1 (en) 1999-04-22
DE69837274T2 (de) 2007-11-08
WO1999018933A3 (en) 1999-07-01
CA2309727C (en) 2012-12-04
CA2309727A1 (en) 1999-04-22
DE69837274D1 (de) 2007-04-19
AU1360499A (en) 1999-05-03
EP1023048B1 (de) 2007-03-07
WO1999018933A2 (en) 1999-04-22
EP1023048A1 (de) 2000-08-02

Similar Documents

Publication Publication Date Title
ATE355826T1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
ATE209887T1 (de) Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel
DE69534760D1 (de) Verfahren zur in-vivo abgabe therapeutischer agenzien mittels liposomen
NO20014231L (no) Innkapsling av bioaktive komplekser i liposomer
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
DE60030970D1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
ATE272393T1 (de) Rekonstruktion gereinigter membranproteine in vorgefertigten liposomen
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
WO2000011176A3 (en) Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation
WO2003063785A3 (en) Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
DE60028152D1 (de) Fester, stabiler und konzentrierter biologisch verdaulicher Komplex von Orthokieselsäure und Prozess zur dessen Herstellung
ATE289806T1 (de) Verfahren zur herstellung pharmazeutischer zusammensetzungen von lipidpartikeln, enthaltend einen lipidwirkstoff sowie ein protein
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
BG101379A (en) New pypimido [1,2-a] indoles
EP0770137A4 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE353368T1 (de) Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen
DE69900653D1 (de) Verfahren zur Herstellung von Säuregruppen enthaltenden Bisxylenolen
FI20000956A0 (fi) Kosmeettinen tai ihonhoidollinen voidekoostumus, sen valmistusmenetelmä ja käyttö
WO1999059638A8 (en) Compositions and methods for the delivery of nucleic acid molecules
Cho et al. Isolation of Sunflower Seed Protein and its Chemical Composition
DE59704883D1 (de) Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties